Evidence map›Paper›PMID 30450642›Full record

Trial reportClinical pharmacology and therapeutics2019

Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole.

Evangelia Liakoni, Hallam Gugelmann, Delia A Dempsey, Timothy J Wiegand, Christopher Havel, Peyton Jacob, Neal L Benowitz

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Inhibition of 1,4-butanediol metabolism in human liver in vitro.Naunyn-Schmiedeberg's archives of pharmacology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Evangelia LiakoniDivision of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, California, USA.
Hallam GugelmannCalifornia Poison Control Center, University of California, San Francisco, California, USA.
Delia A DempseyDivision of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, California, USA.
Timothy J WiegandUniversity of Rochester Medical Center, Rochester, New York, USA.
Christopher HavelDivision of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, California, USA.
Peyton JacobDivision of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, California, USA.
Neal L BenowitzDivision of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, California, USA.
University of California, San Francisco · USPrison University Project · USUniversity of Bern · CHUniversity of Rochester Medical Center · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
CLINICAL, PHARMACOLOGY, DRUG ACTION &PHARMACOKINETICST32GM007546 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Radojka Savic · 1985 to 2026
$8.9M
GHB Abuse: Motivations, Medical consequences, &RisksR01DA014935 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DYER, JO E · 2002 to 2006
$4.3M
NCATS NIH HHS UL1 TR000004NIDA NIH HHS R01 DA014935NIGMS NIH HHS T32 GM007546
6 · The paper itself

Abstract

1,4-Butanediol (BDO)-used as solvent and abused for its euphoric effects-is converted to gamma-hydroxybutyrate (GHB) by the enzyme alcohol dehydrogenase. This double-blind, placebo-controlled crossover study with six healthy volunteers is the first to date investigating the role of the ADH inhibitor fomepizole (4-methylpyrazole (4MP)) in moderating this conversion in humans. Participants received on two different days either intravenous placebo or 15 mg/kg 4MP followed by oral administration of 25 mg/kg BDO. Pretreatment with 4MP resulted in significantly higher BDO maximal plasma concentration (P = 0.001) and area under the concentration-time curve (AUC; P = 0.028), confirming that ADH is the primary pathway for the conversion of BDO to GHB in humans. With 4MP, the mean arterial pressure was significantly lower at 105 minutes compared to baseline (P = 0.003), indicating that blood pressure lowering, observed not with a temporal relationship to 4MP administration but after the maximum BDO concentration was reached, may be an intrinsic effect of BDO.

Indexed as

FomepizoleAdultAlcohol DehydrogenaseButylene GlycolsCross-Over StudiesDouble-Blind MethodDrug MonitoringEnzyme InhibitorsHealthy VolunteersHumansMaleMetabolic Clearance RatePsychotropic DrugsSodium OxybateSolventsTreatment Outcome1,4-butanediolAlcohol DehydrogenaseButylene GlycolsEnzyme InhibitorsFomepizolePsychotropic DrugsSodium OxybateSolvents

Identifiers

PMID30450642
PMCPMC6465153
OpenAlexW2901673810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.